Outcomes of Adrenalectomy and the Aldosteronoma Resolution Score in the Black and Hispanic Population.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
05 2021
Historique:
accepted: 10 01 2021
pubmed: 9 2 2021
medline: 9 7 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

Outcomes after adrenalectomy in patients with primary aldosteronism (PA) are variable. The aldosteronoma resolution score (ARS) uses preoperative variables to calculate a score that identifies those patients that are more likely to have resolution of hypertension after adrenalectomy. We aim to determine the efficacy of adrenalectomy and whether the ARS accurately predicts clinical success in a Black and Hispanic population. We reviewed patients who underwent adrenalectomy for PA from 2004 to 2018 at two academic centers treating primarily Hispanic and Black patients. Postoperative outcomes were evaluated based on the primary aldosteronism surgical outcome consensus criterion. Retrospectively, the accuracy of ARS was determined by a receiver operating characteristic curve and the area under the curve (AUC). Forty-three Hispanic and 10 Black patients underwent adrenalectomy for PA. Twenty-two patients (41.5%) had complete clinical success. Variables associated with complete clinical success in the univariate analysis were female gender (p = 0.026), younger age (p = 0.001), lower preoperative aldosterone (p = 0.035), lower preoperative systolic blood pressure (p = 0.001), fewer number of preoperative antihypertensive medications (p = 0.007) and a higher ARS (p = 0.003). On multivariate analysis, only fewer number of preoperative antihypertensive medications was independently associated with complete clinical success (p = 0.026). The AUC of the ARS was 0.746. The rate of clinical success from adrenalectomy is good for Hispanic and Black patients with PA. Our analysis shows that the ARS is an accurate test of clinical success in Hispanic and Black patients. The ARS may be utilized preoperatively to frame expectations after adrenalectomy in these populations.

Sections du résumé

BACKGROUND
Outcomes after adrenalectomy in patients with primary aldosteronism (PA) are variable. The aldosteronoma resolution score (ARS) uses preoperative variables to calculate a score that identifies those patients that are more likely to have resolution of hypertension after adrenalectomy. We aim to determine the efficacy of adrenalectomy and whether the ARS accurately predicts clinical success in a Black and Hispanic population.
METHODS
We reviewed patients who underwent adrenalectomy for PA from 2004 to 2018 at two academic centers treating primarily Hispanic and Black patients. Postoperative outcomes were evaluated based on the primary aldosteronism surgical outcome consensus criterion. Retrospectively, the accuracy of ARS was determined by a receiver operating characteristic curve and the area under the curve (AUC).
RESULTS
Forty-three Hispanic and 10 Black patients underwent adrenalectomy for PA. Twenty-two patients (41.5%) had complete clinical success. Variables associated with complete clinical success in the univariate analysis were female gender (p = 0.026), younger age (p = 0.001), lower preoperative aldosterone (p = 0.035), lower preoperative systolic blood pressure (p = 0.001), fewer number of preoperative antihypertensive medications (p = 0.007) and a higher ARS (p = 0.003). On multivariate analysis, only fewer number of preoperative antihypertensive medications was independently associated with complete clinical success (p = 0.026). The AUC of the ARS was 0.746.
CONCLUSION
The rate of clinical success from adrenalectomy is good for Hispanic and Black patients with PA. Our analysis shows that the ARS is an accurate test of clinical success in Hispanic and Black patients. The ARS may be utilized preoperatively to frame expectations after adrenalectomy in these populations.

Identifiants

pubmed: 33554297
doi: 10.1007/s00268-021-05967-y
pii: 10.1007/s00268-021-05967-y
pmc: PMC8026410
doi:

Substances chimiques

Aldosterone 4964P6T9RB

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1475-1482

Références

Funder JW et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(5):1889–1916
doi: 10.1210/jc.2015-4061
Yang Y, Reincke M, Williams TA (2019) Prevalence, diagnosis and outcomes of treatment for primary aldosteronism. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2019.101365
doi: 10.1016/j.beem.2019.101365 pubmed: 31837980
Vaidya A, Mulatero P, Baudrand R, Adler GK (2018) The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 39(6):1057–1088. https://doi.org/10.1210/er.2018-00139
doi: 10.1210/er.2018-00139 pubmed: 30124805 pmcid: 6260247
Zarnegar R et al (2008) The Aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247(3):511–518. https://doi.org/10.1097/SLA.0b013e318165c075
doi: 10.1097/SLA.0b013e318165c075 pubmed: 18376197
Utsumi T et al (2012) High predictive accuracy of Aldosteronoma resolution score in Japanese patients with aldosterone-producing adenoma. Surgery 151(3):437–443. https://doi.org/10.1016/j.surg.2011.08.001
doi: 10.1016/j.surg.2011.08.001 pubmed: 22000827
Aronova A, Gordon BL, Finnerty BM, Zarnegar R, Fahey TJ (2014) Aldosteronoma resolution score predicts long-term resolution of hypertension. Surgery 156(6):1387–1393. https://doi.org/10.1016/j.surg.2014.08.019
doi: 10.1016/j.surg.2014.08.019 pubmed: 25456916
Pasquier L et al (2017) Assessment of the aldosteronona resolution score as a predictive resolution score of hypertension after adrenalectomy for aldosteronoma in French patients. Langenbecks Arch Surg 402(2):309–314. https://doi.org/10.1007/s00423-017-1557-x
doi: 10.1007/s00423-017-1557-x pubmed: 28111697
Loh WJ, Lim DST, Loh LM, Kek PC (2018) Factors associated with resolution of hypertension after adrenalectomy in patients with primary aldosteronism. Endocrinol Metab 33(3):355. https://doi.org/10.3803/EnM.2018.33.3.355
doi: 10.3803/EnM.2018.33.3.355
International Connsortium Study Group et al (2019) Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice. World J Surg 43(10):2459–2468. https://doi.org/10.1007/s00268-019-05074-z
doi: 10.1007/s00268-019-05074-z
Kumar J (2013) Epidemiology of hypertension. Clin Queries Nephrol 2(2):56–61. https://doi.org/10.1016/j.cqn.2013.04.005
doi: 10.1016/j.cqn.2013.04.005
Guzman NJ (2012) Epidemiology and management of hypertension in the hispanic population: a review of the available literature. Am J Cardiovasc Drugs 12(3):165–178. https://doi.org/10.2165/11631520-000000000-00000
doi: 10.2165/11631520-000000000-00000 pubmed: 22583147 pmcid: 3624012
Käyser SC et al (2016) Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 101(7):2826–2835. https://doi.org/10.1210/jc.2016-1472
doi: 10.1210/jc.2016-1472 pubmed: 27172433
Gershuni VM et al (2020) Clinical presentation and surgical outcomes in primary aldosteronism differ by race. J Surg Oncol 121(3):456–464. https://doi.org/10.1002/jso.25806
doi: 10.1002/jso.25806 pubmed: 31858609
Williams TA et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5(9):689–699. https://doi.org/10.1016/S2213-8587(17)30135-3
doi: 10.1016/S2213-8587(17)30135-3 pubmed: 28576687 pmcid: 5572673
Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5(9):1315–1316. https://doi.org/10.1097/JTO.0b013e3181ec173d
doi: 10.1097/JTO.0b013e3181ec173d pubmed: 20736804
Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243–1248. https://doi.org/10.1016/j.jacc.2005.01.015
doi: 10.1016/j.jacc.2005.01.015 pubmed: 15837256
Funder JW (2018) Primary aldosteronism and cardiovascular risk, before and after treatment. Lancet Diabetes Endocrinol 6(1):5–7
doi: 10.1016/S2213-8587(17)30368-6
Catena C et al (2007) Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50(5):911–918. https://doi.org/10.1161/HYPERTENSIONAHA.107.095448
doi: 10.1161/HYPERTENSIONAHA.107.095448 pubmed: 17893375
Zeiger M et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas. Endocr Pract 15(Supplement 1):1–20. https://doi.org/10.4158/EP.15.S1.1
doi: 10.4158/EP.15.S1.1 pubmed: 19632967
Burrello J et al (2019) The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg. https://doi.org/10.1097/SLA.0000000000003200
doi: 10.1097/SLA.0000000000003200

Auteurs

Gustavo Romero-Velez (G)

General Surgery, Department of Surgery, Montefiore Medical Center, The Bronx, NY, USA.

Amanda M Laird (AM)

Section of Endocrine Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Manuel E Barajas (ME)

Division of Endocrine Surgery, Department of General Surgery, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Mexico City, Mexico.

Mauricio Sierra-Salazar (M)

Division of Endocrine Surgery, Department of General Surgery, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Mexico City, Mexico.

Miguel F Herrera (MF)

Division of Endocrine Surgery, Department of General Surgery, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Mexico City, Mexico.

Steven K Libutti (SK)

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Michael K Parides (MK)

Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, The Bronx, NY, USA.

Xavier Pereira (X)

General Surgery, Department of Surgery, Montefiore Medical Center, The Bronx, NY, USA.

John C McAuliffe (JC)

Surgical Oncology, Department of Surgery, Montefiore Medical Center, 1865 Eastchester Rd. Suite 2S7, Bronx, NY, 10461, USA. jomcauli@montefiore.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH